Occlutech receives subscription commitment for €40 million of bonds

Chicago, April 6 – Occlutech Holding AG received a €40 million subscription commitment by funds advised by Ture Invest Partners AB, according to a press release.

The first tranche was issued on March 31, under a €75 million framework.

The bonds mature Dec. 31, 2027.

Proceeds will be used to finance the upcoming launch of the atrial septal defect occluder in the United States and continued growth in Occlutech's established markets. Proceeds from the bonds will also be used to finance the ongoing global FDA studies related to the atrial flow regulator device.

Carnegie Investment Bank acted as financial adviser to Occlutech.

Occlutech is a specialist provider of minimally invasive structural heart implants, based in Schaffhausen, Switzerland.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.